How did FBIO's revenue and expenses trend in Q4 2024?

Fortress Biotech (FBIO) experienced a decline in revenue and an increase in expenses in Q4 2024, resulting in a negative net income.

1. **Revenue Trend**: FBIO's total revenue for Q4 2024 was $15.12 million, representing a year-over-year growth rate of -0.24%. This indicates a slight decrease in revenue compared to the same period last year.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|FBIO|FBIO.O|Fortress Biotech|2024 Q1|4.835465443720331|1.303E7|186|
|FBIO|FBIO.O|Fortress Biotech|2024 Q2|-14.321868169791788|1.4896E7|186|
|FBIO|FBIO.O|Fortress Biotech|2024 Q3|-57.90458103130756|1.4629E7|186|
|FBIO|FBIO.O|Fortress Biotech|2024 Q4|-24.19532738393663|1.512E7|186|

|code|Ticker|Name|Date|R&D Expenses|Net Income|market_code|
|---|---|---|---|---|---|---|
|FBIO|FBIO.O|Fortress Biotech|2024 Q1|2.4839E7|-3.9023E7|186|
|FBIO|FBIO.O|Fortress Biotech|2024 Q2|1.2671E7|-2.8824E7|186|
|FBIO|FBIO.O|Fortress Biotech|2024 Q3|9446000|-2.6694E7|186|
|FBIO|FBIO.O|Fortress Biotech|2024 Q4|9688000|-2.6315E7|186|

2. **Expense Trend**: The total expenses for FBIO in Q4 2024 were $19.95 million. Without comparative data for the previous year, it is not possible to assess the trend of expenses alone.
3. **Net Income**: The net income for FBIO in Q4 2024 was -$26.32 million. This negative net income suggests that the company incurred more expenses than it generated in revenue during the quarter.

In conclusion, FBIO faced a challenging quarter in Q4 2024, with revenue declining slightly and expenses exceeding revenue, leading to a substantial negative net income.